Time for a successful cancer vaccine in NSCLC?
Mené sur 222 patients atteints d'un cancer avancé du poumon non à petites cellules, cet essai randomisé international de phase 2b évalue l'efficacité, du point de vue de la survie sans progression, de la combinaison d'un vaccin thérapeutique, à base d'un virus Ankara modifié pour exprimer la protéine MUC1 et l'interleukine 2, et d'une chimiothérapie de première ligne
In the past couple of years, there has been a resurgence in interest in cancer immunotherapy. Much of the excitement has been generated by positive randomised phase 3 trials of checkpoint inhibitors in advanced melanoma and non-small-cell lung cancer. Investigators of two phase 3 trials of nivolumab, a monoclonal antibody against PD-1, for second-line treatment of advanced non-small-cell lung cancer have reported significant improvements in overall survival and the proportion of patients achieving a response compared with standard cytotoxic chemotherapy.
The Lancet Oncology , commentaire, 2014